ERBB2 and breast cancer: Recent results demonstrated that pyrotinib, an irreversible pan‐ERBB2 inhibitor, increased DNA damage and enhanced the radiosensitivity of HER2‐overexpressing gastric and breast cancer cells in vitro and in vivo.